Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 941, doi. 10.1002/cpdd.982
- Publication type:
- Article
Works matching IS 2160763X AND DT 2023 AND VI 12 AND IP 10
Results: 12
1
2
Correction to Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1,Open‐Label, Single‐Dose, Parallel‐Group Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 1045, doi. 10.1002/cpdd.1326
- Publication type:
- Article
3
Pharmacokinetics, Tolerability, and Safety of Glecaprevir/Pibrentasvir Co‐formulated Bilayer Tablet Following Repeated Administration in Healthy Chinese Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 945, doi. 10.1002/cpdd.1325
- By:
- Publication type:
- Article
4
Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 956, doi. 10.1002/cpdd.1308
- By:
- Publication type:
- Article
5
Pharmacokinetic Profiles of a Proposed Biosimilar Ustekinumab (BFI‐751): Results From a Randomized Phase 1 Trial.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 1001, doi. 10.1002/cpdd.1305
- By:
- Publication type:
- Article
6
Phase 1, Single‐ and Multiple‐Ascending‐Dose, Food‐Effect, and East Asian Subject Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Bempedoic Acid, a Selective Inhibitor of Adenosine Triphosphate Citrate Lyase.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 1022, doi. 10.1002/cpdd.1297
- By:
- Publication type:
- Article
7
Pharmacokinetics and Bioequivalence of Mirogabalin Orally Disintegrating Tablets and Conventional Tablets in Healthy Japanese Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 985, doi. 10.1002/cpdd.1292
- By:
- Publication type:
- Article
8
Model‐Based Dose Selection of Fostemsavir for Pediatric Populations With Multidrug‐Resistant HIV‐1 and Relative Bioavailability Assessment in Healthy Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 991, doi. 10.1002/cpdd.1291
- By:
- Publication type:
- Article
9
Pharmacokinetics, Safety, and Tolerability of Vonoprazan‐ or Esomeprazole‐Based Bismuth‐Containing Quadruple Therapy: A Phase 1, Double‐Blind, Parallel‐Group Study in Adults with Helicobacter pylori Infection in China.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 1036, doi. 10.1002/cpdd.1276
- By:
- Publication type:
- Article
10
Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open‐Label, Drug–Drug Interaction Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 1013, doi. 10.1002/cpdd.1267
- By:
- Publication type:
- Article
11
Effect of Food on the Pharmacokinetics of Limertinib (ASK120067) and its Main Metabolite in Healthy Chinese Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 979, doi. 10.1002/cpdd.1266
- By:
- Publication type:
- Article
12
Evaluation of the Cytochrome P450 3A and P‐glycoprotein Drug‐Drug Interaction Potential of Futibatinib.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 966, doi. 10.1002/cpdd.1259
- By:
- Publication type:
- Article